BBBibhusan Basnet

Bibhusan Basnet

*This is an algorithmically generated author record based on publicly available information.

Bibhusan Basnet has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis

    by Himal Bikram Bhattarai, Basanta Sharma Paudel, Sandesh Raman Parajuli, Krishna Dahal, Sangam Shah, Madhur Bhattarai, Bidisha Baral, Bibek Karki, Bibhusan Basnet, Amit Bhandari, et al.

    Background: Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly prescribed for diabetes mellitus and weight loss, often cause gastrointestinal side effects in both their oral and injectable forms. Recently, oral non-peptide GLP-1 receptor agonists like danuglipron and orforglipron, which are smaller and more stable, have been investigated. This study analyzes the gastrointestinal side effects of these newer, smaller molecules. Methods: We performed a systematic review of the literature databases like PubMed, Cochrane, Embase, and clinicaltrials.gov until November 2023. Data related to different doses of oral danuglipron and orforglipron and their gastrointestinal side effects including nausea, vomiting, constipation, diarrhea, eructation, and dyspepsia were obtained. Analysis was done using RevMan v5.4 (The Cochrane Collaboration, Copenhagen, Denmark). Results: We included a total of 4 studies of which 2 each were for danuglipron and orforglipron. The oral doses of orforglipron studied were 12 mg, 24 mg, 36 mg, and 45 mg, with nausea being the most common side effect in all groups. For the 45 mg dose of orforglipron, the odds ratio (OR) was 4.41 (95% CI: 2.90–6.71), while the 36 mg dose had an OR of 3.99 (95% CI: 2.22–7.18). The OR for the 24 mg dose was 5.66 (95% CI: 3.39–9.45), and the 12 mg dose showed an OR of 5.06 (95% CI: 3.31–7.73). Oral danuglipron at doses of 80 mg and 120 mg were also studied. The 120 mg dose of danuglipron had a pooled OR of 4.38 (95% CI: 2.30–8.34) while the 80 mg dose had an OR of 3.69 (95% CI: 1.77–7.67) indicating a significant decrease in gastrointestinal side effects. Conclusion: Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists were widely reported but less frequent compared to placebo/ standard treatment. There was no significant dose-dependent increase in the side effects of these medications.


  • Open Access

    Use of Venous Thromboembolism Prophylaxis in Hospitalized Patients: Knowledge and Practice Among Physicians in Nepal.

    by Amit Bhandari, Amit Khanal, Pratikshya Thapa, Ashish Thapa, Kushal Bhattarai, Bibhusan Basnet

    Despite the importance of Venous Thromboembolism (VTE) prophylaxis in hospitalized patients, audits have shown inadequate use of VTE prophylaxis methods around the world. We aimed to assess knowledge, attitudes, and behaviors regarding VTE prophylaxis among clinicians in Nepal. Methodology: A cross-sectional questionnaire-based survey was conducted using an online survey platform. Results: 199(60.7%) of the respondents were aware of the risk factors-based risk stratification approach to VTE prophylaxis in hospitalized patients. Only 154 (47%) of the physicians reported institute-based protocols for VTE prophylaxis. Conclusion: We found a significant lack of awareness on risk factors-based stratification strategy for VTE prevention practices among Nepalese physicians. We recommend educational efforts for Nepalese physicians on the overall impact of VTE on mortality and morbidity of hospitalized patients. Our study highlights the needs for adoption of institution-based protocols for VTE prophylaxis and prevention.


  • Quality of YouTube patient information on prostate cancer screening

    by Bibhusan Basnet, Suraj Bhattarai, Amit Khanal, Manisha Upadhyay, Ashma Baruwal

    Social media is used by patients for health care information. We analyzed the quality of YouTube videos on prostate cancer screening. Most videos (71.1%) mentioned the potential harms of prostate cancer screening. There was no significant difference in risk-related information between videos published before and after the publication of US Preventive Services Task Force 2012 guidelines for prostate cancer screening. In conclusion, the quality of information of YouTube videos on prostate cancer screening is low and the content is potentially misleading.


  • Open Access

    YouTube lens to attention deficit hyperactivity disorder: a social media analysis

    by Pratikshya Thapa, Ashish Thapa, Nabina Khadka, Ruchi Bhattarai, Samir Jha, Amit Khanal, Bibhusan Basnet

    Social media has provided an online environment for patients to discuss regarding their health and seek medical information. The primary aim of our study was to analyze the quality of information shared on YouTube regarding attention deficit hyperactivity disorder (ADHD). More than half of the videos, 91 (57.23%) had duration of fewer than 5 min. Only 8 (5.03%) videos were rated as highly useful whereas 61 (38.36%) videos were misleading. Interestingly, there was a significant higher (1203.38 ± 395) likes in the misleading group of videos, compared to 162.13 ± 169.63 likes in the very useful group, P = 0.012. Only a small fraction of videos had very useful information on ADHD. There is a need for high-quality, evidence-based, educational videos on ADHD for patient education.


  • Open Access

    Strengthening Nepal’s Female Community Health Volunteer network: a qualitative study of experiences at two years

    by Dan Schwarz, Ranju Sharma, Chhitij Bashyal, Ryan Schwarz, Ashma Baruwal, Gregory Karelas, Bibhusan Basnet, Nirajan Khadka, Jesse Brady, Zach Silver, et al.

    Nepal’s Female Community Health Volunteer (FCHV) program has been described as an exemplary public-sector community health worker program. However, despite its merits, the program still struggles to provide high-quality, accessible services nation-wide. Both in Nepal and globally, best practices for community health worker program implementation are not yet known: there is a dearth of empiric research, and the research that has been done has shown inconsistent results.


  • Open Access

    Strengthening Free Healthcare in Rural Nepal

    by Bibhusan Basnet, Bikash Gauchan, Rishav Shrestha, Ashma Baruwal, Gregory Karcles, Zach Silver

    Nepal, a mountainous country in South East Asia, still lags in increasing access to healthcare and reducing health inequity. Possible Non Government Organization based in Achham, Nepal, which is a sister organization of Possible International Non Government Organization based in New York, USA recognized the increasing health needs in the far western rural hilly parts of Nepal, where extreme poverty and illiteracy was creating a vulnerable picture especially in Achham. Possible (previously named Nyaya Health) started to operate Bayalpata Hospital in 2009 after completing more than one year of free health services in Sanfe-Bagar, Achham, in partnership with the Nepalese Ministry of Health and Population. It supports the idea that free health service has its own challenges but a public-private partnership can thrive while promote equity in health services. Keywords: achham; free health care; nepal; nyaya health; possible.